|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
9
|
Resverlogix Corp.
|
Jun 13, 2023 08:21AM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
4
|
Resverlogix Corp.
|
Jun 13, 2023 05:38PM
|
|
Re: Resverlogix Announces Overnight Marketed Equity Offering
|
4
|
Resverlogix Corp.
|
Jun 08, 2017 05:15PM
|
|
Re: Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
|
6
|
Resverlogix Corp.
|
Nov 12, 2020 09:59AM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
4
|
Resverlogix Corp.
|
Aug 04, 2020 04:03PM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
8
|
Resverlogix Corp.
|
Aug 04, 2020 05:00PM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
4
|
Resverlogix Corp.
|
Aug 04, 2020 11:07PM
|
|
Re: Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
|
2
|
Resverlogix Corp.
|
Mar 15, 2017 08:16AM
|
|
Re: Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
|
3
|
Resverlogix Corp.
|
Mar 15, 2017 08:17AM
|
|
Re: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
|
2
|
Resverlogix Corp.
|
Jun 21, 2023 08:37AM
|
|
Re: RESVERLOGIX CORP. Annual And Special Meeting: December 22, 2020
|
1
|
Resverlogix Corp.
|
Nov 25, 2020 08:28AM
|
|
Re: Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
|
8
|
Resverlogix Corp.
|
Aug 23, 2022 09:06AM
|
|
Re: Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease
|
4
|
Resverlogix Corp.
|
Aug 23, 2022 10:54PM
|
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
3
|
Resverlogix Corp.
|
Oct 04, 2023 10:05AM
|
|
Re: Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
|
4
|
Resverlogix Corp.
|
Jul 10, 2017 08:37AM
|
|
Re: Reverse Split, the good, bad and in between....
|
3
|
Resverlogix Corp.
|
Aug 14, 2018 12:10AM
|
|
Re: Reverse Split, the good, bad and in between....
|
4
|
Resverlogix Corp.
|
Aug 14, 2018 12:24AM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
7
|
Resverlogix Corp.
|
Jun 14, 2020 05:08PM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
|
Resverlogix Corp.
|
Jun 15, 2020 10:18PM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
15
|
Resverlogix Corp.
|
Jun 13, 2020 10:50AM
|
